In relation to chemotherapeutic response, ANRIL has also been reported to promote cell chemoresistance, in multiple cancer types, to various therapeutic agents including cisplatin [33,34,35,36,37,52,53,54]. The gene discussed is CDKN2B-AS1; the disease is cancer.